Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential

被引:36
作者
Fortuin, Ansje S. [1 ]
Smeenk, Robert Jan [2 ]
Meijer, Hanneke J. M. [2 ]
Witjes, Alfred J. [3 ]
Barentsz, Jelle O. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6500 HB Nijmegen, Netherlands
关键词
Urology; Prostate Cancer; Lymph Node Metastases; USPIO; Combidex; Ferumoxtran-10; MRI; MRL; Nanoparticle; LYMPH-NODE METASTASES; ULTRASMALL-SUPERPARAMAGNETIC-PARTICLES; IRON-OXIDE-ALLOW; BIOCHEMICAL RECURRENCE; GLEASON SCORE; LYMPHOGRAPHY; RISK; BLADDER; LYMPHANGIOGRAPHY; RADIOTHERAPY;
D O I
10.1007/s11934-013-0389-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nodal staging in prostate cancer is suboptimal both with respect to current imaging modalities and pelvic lymph node dissection, and thus other techniques are being explored. Lymphotropic nanoparticle-enhanced MRI, also called magnetic resonance lymphography (MRL), is a technique that has shown high sensitivity (65-92 %) and excellent specificity (93-98 %) in detecting prostate cancer lymph node metastases. This technique aids in the detection of metastases in non-enlarged small nodes. MRL has been useful in determining the location and pathways of spread in nodal chains. Knowledge of the location of lymph node involvement is important for decisions regarding appropriate therapeutic options, such as image-guided therapy.. A geographic miss in radiotherapy can be avoided with the use of MRL-guided focal therapy. This paper provides an overview of current literature, lessons learned, and new therapeutic options with nanoparticle-enhanced MRI.
引用
收藏
页数:7
相关论文
共 55 条
[1]   PHASE I TRIAL OF PELVIC NODAL DOSE ESCALATION WITH HYPOFRACTIONATED IMRT FOR HIGH-RISK PROSTATE CANCER [J].
Adkison, Jarrod B. ;
McHaffie, Derek R. ;
Bentzen, Soren M. ;
Patel, Rakesh R. ;
Khuntia, Deepak ;
Peteret, Daniel G. ;
Hong, Theodore S. ;
Tome, Wolfgang ;
Ritter, Mark A. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (01) :184-190
[2]   PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].
Afshar-Oromieh, A. ;
Malcher, A. ;
Eder, M. ;
Eisenhut, M. ;
Linhart, H. G. ;
Hadaschik, B. A. ;
Holland-Letz, T. ;
Giesel, F. L. ;
Kratochwil, C. ;
Haufe, S. ;
Haberkorn, U. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495
[3]   [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH [J].
Afshar-Oromieh, A. ;
Haberkorn, U. ;
Eder, M. ;
Eisenhut, M. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 (06) :1085-1086
[4]  
Afshar-Oromieh A, 2013, EUR J NUCL MED MOL I
[5]   Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer [J].
Allaf, ME ;
Palapattu, GS ;
Trock, BJ ;
Carter, HB ;
Walsh, PC .
JOURNAL OF UROLOGY, 2004, 172 (05) :1840-1844
[6]   68Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer [J].
Banerjee, Sangeeta Ray ;
Pullambhatla, Mrudula ;
Byun, Youngjoo ;
Nimmagadda, Sridhar ;
Green, Gilbert ;
Fox, James J. ;
Horti, Andrew ;
Mease, Ronnie C. ;
Pomper, Martin G. .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5333-5341
[7]   Iron oxide-enhanced MR lymphography: initial experience [J].
Bellin, MF ;
Beigelman, C ;
Precetti-Morel, S .
EUROPEAN JOURNAL OF RADIOLOGY, 2000, 34 (03) :257-264
[8]   Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy [J].
Berkovic, Patrick ;
De Meerleer, Gert ;
Delrue, Louke ;
Lambert, Bieke ;
Fonteyne, Valerie ;
Lumen, Nicolaas ;
Decaestecker, Karel ;
Villeirs, Geert ;
Vuye, Philippe ;
Ost, Piet .
CLINICAL GENITOURINARY CANCER, 2013, 11 (01) :27-32
[9]  
Birkhauser FD, 2013, EUR UROL IN PRESS
[10]   The role of lymphadenectomy in high risk prostate cancer [J].
Burkhard, Fiona C. ;
Studer, Urs E. .
WORLD JOURNAL OF UROLOGY, 2008, 26 (03) :231-236